GlobalData on MSN3d
Nammi Therapeutics doses first subject in trial of QXL138AM for multiple myeloma
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...
Pharmabiz3d
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...
The Victoria Advocate7d
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- Nammi Therapeutics ... solid tumor indications with high CD138 prevalence and multiple myeloma) with primary endpoints focused on safety and tolerability ...
BioSpace13h
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...
The Globe and Mail17d
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma. RAPA-201: Rapa Therapeutics RAPA-201 It is a type of autologous cell therapy. The drug ...
Medscape1d
Immunomodulatory Drugs in Multiple Myeloma
This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...
Medscape3d
Kyphoplasty for Patients With Multiple Myeloma is a Safe Surgical Procedure: Results From a Large Patient Cohort
The data of 76 patients with 190 kyphoplasty-treated vertebrae were analyzed retrospectively (Figure 3). In our collective, the standard postoperative CT of the kyphoplasty-treated vertebrae ...
Medindia7d
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), a clinical stage ... cohorts (two solid tumor indications with high CD138 prevalence and multiple myeloma) with primary ...